A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

OSTEOAMPĀ® SELECT Flowable Allograft Bone Graft Launches Reports Bioventus

OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures including lumbar spine fusion, cervical spine fusion, and foot & ankle fusion has been launched by Bioventus.

Introduced in a limited release in select US markets beginning in March 2021, OSTEOAMP SELECT Flowable is 100 percent allograft with no synthetic carrier added, yet still based on the unique OSTEOAMP process designed to retain a wide array of essential growth factors. * Its versatile handling is designed to satisfy the need for a flowable allograft product with cohesive properties, making it an attractive option for minimally invasive surgery (MIS), expandable cages and 3D-printed cages.

ā€œSpine, trauma and foot & ankle surgeons are looking for allograft options that handle well for a variety of procedures,ā€ said Dr. Larry Boyd, Vice President, Product Development, Bioventus. ā€œDeveloped by our team in collaboration with our tissue bank partner, OSTEOAMP SELECT Flowable comes ready-to-use and is designed to be delivered in a range of methods and to provide excellent retention characteristics at the grafting site. It is terminally sterilized and processed using advanced procedures designed to comply with the highest standards for tissue banking, including comprehensive donor screening and extensive microbiological testing.ā€

“OSTEOAMP SELECT Flowable has been an ideal product for a variety of my minimally invasive interbody fusions, particularly with expandable cage technology, where I need a graft that handles efficiently to navigate tight spaces,ā€ said Dr. Paul Kim, Carolina Neurosurgery & Spine Associates. ā€œI have used various formats of OSTEOAMP for years and have seen firsthand the successful patient outcomes it can help provide.ā€

ā€œA differentiated allograft product with the handling characteristics like OSTEOAMP SELECT Flowable is an asset for a spine surgeon who uses 3D printed cages where grafting can be challenging,ā€ said Dr. Safdar Khan, Ohio State University. ā€œI was impressed to see how the flowable product filled a cage with a tight, porous structure so well and stayed in place during implantation.ā€

OSTEOAMP SELECT Flowable comes in three sizes from 2.5 to 10 cc and is available nationwide.

*In vitro performance may not be predictive of performance in humans.

SourceBioventus
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ā„¢ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZenecaā€™s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomixā€™s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
ā€œSince the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,ā€ she said. ā€œWe wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physiciansā€™ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy